The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography

What Was Tested

This randomized controlled trial paper looks at Octreotide in the context of pancreatitis (after the acute phase).

Sixty-three consecutive patients undergoing ERCP were randomly allocated to two group.

Who Took Part

According to the abstract, 34 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Octreotide.

What Was Measured

PubMed files the paper under topics including Acute Disease, Amylases, Cholangiopancreatography, Endoscopic Retrograde, Lipase, Octreotide and Pancreatitis.

What This Means in Plain Language

The paper is a randomized and double-blind study of Octreotide in 34 patients in people with pancreatitis (after the acute phase).

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1991 (Gastrointestinal endoscopy), a journal based in United States.

More context: the Octreotide compound page, Pancreatitis (after the acute phase) research.